1-800-887-8100
COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
MENU
Shared Solutions®
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
Copaxone® is the #1 prescribed brand for relapsing MS in the US 1*

Trust Teva​‌’s Shared Solutions® to be your partner for patient support

Teva’s Shared Solutions® offers a full range of services for patients taking Teva​‌'s COPAXONE®

CONTACT TEVA’S
SHARED SOLUTIONS®
DIRECTLY
Call
1-800-887-8100
And Press 1 for Copaxone®

Teva’s Shared Solutions® can take care of many important behind-the-scenes details so you can focus on treating your patients

When you prescribe Teva’s COPAXONE®, you and your patients can trust in the comprehensive patient services and support provided by Teva’s Shared Solutions®

Healthcare Professional Services
Full range of services to help manage your patients on COPAXONE®

*Applies only to 3-times-a-week COPAXONE® 40 mg. Certain limits and restrictions apply. See Terms and Conditions.

Teva’s Shared Solutions® is a personalized approach to helping patients start and stay committed to 3-times-a-week COPAXONE® 40 mg/mL

Financial Solutions
Helping your patients find financial solutions to start and stay on their COPAXONE® treatment

Support for Starting Therapy
Starting your patients on COPAXONE®

Support for Staying Compliant
Helping your patients stay committed with COPAXONE®

Injection Training
In-home instruction for patients at any stage of therapy

Teva’s Shared Solutions® is committed to helping your patients find financial solutions to start and stay on their COPAXONE® treatment
Explore financial solutions
Teva’s Shared Solutions® offers a full range of support services to help your COPAXONE® patients reach their treatment goals
See all services
Teva’s Clinical Nurse Educators (CNEs) offer personalized services and support for you, your patients, and the RMS community
View CNE services

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

IMPORTANT SAFETY INFORMATION

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of

You are now leaving this website

The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.

While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.

Continue to site
×